Agios Will Find Out Whether Thalassemia Revenue Can Carry the Conversation Past February

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Agios typically reports earnings before the market opens, meaning Day 0 captures the first full trading session where investors react to results, while Day +1 reflects follow-through momentum.

Agios has exhibited volatile post-earnings price action, with an average absolute Day 0 move of 4.30% and Day +1 move of 2.37%. The stock's reaction has been highly directional, with several double-digit swings in recent quarters.

The most dramatic recent move came in April 2026, when shares surged 13.10% on earnings day with a 12.78% intraday range, though momentum faded by Day +1. The July 2026 report triggered a 6.46% decline on Day 0, followed by an 8.34% drop on Day +1, reflecting investor disappointment despite the earnings beat. Earlier reports in February and October 2025 produced more muted reactions, with Day 0 moves of just 1.30% and 2.91%, respectively.

The historical pattern suggests investors react strongly to revenue trends and pipeline updates rather than just the EPS beat/miss. The wide Day 0 range of 8.67% on average indicates significant intraday volatility as traders digest results and management commentary. Given the recent sickle cell regulatory delay and heightened focus on thalassemia launch metrics, this quarter could see elevated volatility if results or guidance deviate meaningfully from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.15% expected move by the November 20 expiration (16 days out), implying a range of $28.84 to $33.96. This is notably higher than the stock's average historical Day 0 move of 4.30% but roughly in line with the 8.67% average Day 0 range, suggesting options traders are anticipating elevated volatility around this report given the recent regulatory uncertainty and heightened focus on commercial execution.

Part 3: What Analysts Are Saying

Agios enjoys strong analyst support, with a consensus rating of 4.27 out of 5.0 (between Buy and Strong Buy) based on 11 analysts. The breakdown shows 7 Strong Buys, 0 Moderate Buys, 4 Holds, 0 Moderate Sells, and 0 Strong Sells—a decidedly bullish stance.

The average price target sits at $44.33, implying 41% upside from the current price of $31.38. Targets range from a low of $32.00 to a high of $72.00, reflecting divergent views on the company's commercial potential and pipeline value.

Analyst sentiment has remained unchanged over the past month, with the same 7 Strong Buys and 4 Holds. This stability is notable given the recent FDA delay on the sickle cell application, suggesting the Street views the setback as temporary rather than a fundamental threat to the investment thesis. The consensus appears to be that AQVESME's thalassemia launch momentum and the eventual sickle cell approval in early 2027 will drive meaningful value creation, with the current price offering an attractive entry point relative to the $44.33 average target.

Part 4: Technical Picture

Agios is trading below all major moving averages, reflecting recent weakness following the October 30 FDA announcement of the sickle cell regulatory delay. The stock closed at $31.38, below the 5-day ($32.06), 10-day ($34.75), 20-day ($33.78), 50-day ($33.48), 100-day ($34.61), and 200-day ($31.75) moving averages.

The Barchart Technical Opinion has deteriorated sharply, currently showing a 24% Sell signal compared to a 72% Buy signal just one week ago and a 24% Sell signal one month ago. This dramatic reversal reflects the market's negative reaction to the sickle cell delay, which triggered a gap down from $37.23 to $31.43 on November 1.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests the immediate downtrend may be stabilizing after the sharp selloff
• Medium-term (Hold): Consolidation in the intermediate timeframe indicates indecision as investors weigh thalassemia launch progress against sickle cell timing
• Long-term (50% Sell): Moderate sell signal reflects weakness in the longer-term trend, though not an extreme bearish reading

Trend Characteristics: The combination of Minimum strength and Weakest direction indicates the stock is in a fragile technical position heading into earnings, with limited momentum and vulnerability to further downside if results disappoint.

The technical setup is cautionary heading into earnings. Trading below all key moving averages and just 1.2% above the 200-day at $31.75, the stock has limited technical support nearby. The 200-day represents a critical floor—a break below could trigger further selling toward the $28.84 lower end of the options-implied range. Conversely, a strong earnings beat with positive thalassemia commentary could spark a relief rally back toward the 50-day at $33.48 or even the 10-day at $34.75. The weak momentum and bearish short-term sentiment suggest the path of least resistance is lower unless management delivers a clear catalyst to reverse the recent technical damage.